RxDoctor Payments Data

Patrick Adler, DO

Family Medicine · Yardley, PANPI 1346322161

Payments from drug & device makers

$962in general payments, 2019–2025

Across 21 payments — averaging $45.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$237
  • Amarin Pharma, Inc.$125
  • Johnson & Johnson$118
  • AbbVie$110
  • Novartis$100
  • AstraZeneca$100
  • plus $172 from 8 others

What the payments were for

  • Food & beverage$962100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$962 in reported general payments places this provider in the 65th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$77,306
Medicare patients
186
Services billed
1,021

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide90$103,073
CopaxoneGlatiramer Acetate13$74,599
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl302$61,129
JardianceEmpagliflozin35$50,928
XareltoRivaroxaban65$45,156
EliquisApixaban40$39,170
JanuviaSitagliptin Phosphate33$39,051
FarxigaDapagliflozin Propanediol25$26,100
OxycontinOxycodone Hcl26$21,200
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$20,772
JanumetSitagliptin Phos/Metformin Hcl19$18,355
Morphine Sulfate ErMorphine Sulfate165$17,555
Xtampza ErOxycodone Myristate32$15,129
LinzessLinaclotide18$14,957
BrilintaTicagrelor13$13,106

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Copaxone$11$74,59913 claims
MerckJanuvia, Janumet, Dulera$13$64,89474 claims
Johnson & JohnsonXarelto$118$45,15665 claims
AstraZenecaFarxiga, Brilinta$100$39,20638 claims
PfizerEliquis$11$39,17040 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$237$35,10959 claims
AbbVieLinzess$110$14,95718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Yardley

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →